Institutes and Centers
The Cancer Prevention Precision Control Institute (CPPCI) leverages innovative behavioral science and health communication methodologies to address cancer disparities, community outreach and engagement, and improved health outcomes across the cancer care continuum.
The Institute for Multiple Myeloma and Lymphoma (iMML) expedites the development of breakthrough ideas relating to the treatment of multiple myeloma to their full expression in preclinical studies, clinical trials and approved interventions, ultimately offering life-saving care for patients.
The Institute for Immunologic Intervention (3i) examines and develops the knowledge of T cell development, infection immunity, autoimmune inflammation, tumor immunity and alloimmunity.
The Center for Excellence in Translational Research (CETR) program serves as an engine to develop selected optimized Leads and Preclinical Development Candidates (PDCs) against high-threat MDR GP and GN bacteria including Mycobacterium tuberculosis (Mtb) and Nontuberculous Mycobacteria (NTMs).
The Metropolitan Anti-Viral Drug Accelerator (MAVDA) is dedicated to to conduct innovative, multidisciplinary research to develop, optimize and test innovative small molecule antiviral drugs that target coronaviruses (such as SARS-CoV-2), and other viral families with high potential to cause a pandemic in the future.